Syndexa Pharmaceuticals Corp. Expands Series B1 Financing Round With $8.5 Million Investment by MP Healthcare Venture Management
“This funding from new investor, MP Healthcare Venture Management, and support from Tetsuro Iwata comes at an important time for Syndexa,” said Teo Uysal, President and CEO. “The proceeds from our Series B1 will enable us to progress the preclinical development of our Endoplasmic Reticulum (ER) modulating compounds towards development candidate selection, and will allow us to validate the therapeutic potential of our most promising compounds in various indications of ER dysfunction.”
About MP Healthcare Venture Management
MP Healthcare Venture Management, Inc. (MPH) is a lifesciences venture capital firm, investing in innovative companies developing novel therapeutics, platform technologies, vaccines and diagnostics. MPH invests in seed to late stage private companies, and investment is not limited by geographic region. MPH is a jointly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Chemical Holdings Corporation (MCHC). For more information, visit www.mp-healthcare.com.
About Syndexa Pharmaceuticals
Syndexa is dedicated to the discovery and development of a new generation of small-molecule drugs targeting novel mechanisms for the treatment and prevention of diseases of endoplasmic reticulum (ER) dysfunction which include inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases. Founded by leading scientists from Harvard University, the company has raised $24.8M of equity capital to date and is executing on its business strategy to rapidly build and commercialize a portfolio of breakthrough products. The company is headquartered in Watertown, MA. For additional information, please visit www.syndexa.com.
For more information, please contact info@syndexa.com.
Contact:
Syndexa Pharmaceuticals Corp.
Teo Uysal, 617-349-1660